Aristotle Atlantic Partners, LLC Vertex Pharmaceuticals Inc Transaction History
Aristotle Atlantic Partners, LLC
- $3.16 Billion
- Q4 2024
A detailed history of Aristotle Atlantic Partners, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Aristotle Atlantic Partners, LLC holds 51,251 shares of VRTX stock, worth $25 Million. This represents 0.65% of its overall portfolio holdings.
Number of Shares
51,251
Previous 54,094
5.26%
Holding current value
$25 Million
Previous $25.2 Million
17.97%
% of portfolio
0.65%
Previous 0.79%
Shares
14 transactions
Others Institutions Holding VRTX
# of Institutions
1,760Shares Held
228MCall Options Held
1.63MPut Options Held
1.47M-
Capital World Investors Los Angeles, CA28.3MShares$13.8 Billion1.8% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.3MShares$11.4 Billion0.17% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$10.4 Billion0.23% of portfolio
-
State Street Corp Boston, MA12MShares$5.85 Billion0.2% of portfolio
-
Capital Research Global Investors Los Angeles, CA10.4MShares$5.09 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $125B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...